---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-26-000032"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2026-07-23T20:00:24+00:00"
generated_at: "2026-07-23T20:01:15.795199+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q2 2026 revenue $153.6M (+12.8% YoY); net income $9.0M vs loss a year ago

## Summary
- Worldwide revenue $153.6M, up 12.8% YoY (12.4% constant currency); U.S. revenue $125.6M (+13.6%).
- Net income $9.0M ($0.18 EPS) vs net loss of $0.13 per share in Q2 2025; adjusted EBITDA $27.3M (+78%).
- Gross margin 77.2%, up 269 bps YoY; income from operations $9.7M vs loss of $6.2M.
- Growth driven by cryoSPHERE MAX pain management probe, EnCompass clamp, AtriClip devices; international revenue $28.0M (+9.6%).
- Advancing BoxX-NoAF and LeAAPS clinical trials towards data readouts.

## SEC filing metadata
- accession: 0001323885-26-000032
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2026-07-23T20:00:24+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/0001323885-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/atrc-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-26-000032
- JSON: https://secwatch.observer/filing/0001323885-26-000032.json
- Plain text: https://secwatch.observer/filing/0001323885-26-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.